Mediso Completes Technology Transfer of Novel MRI spectrometer

Mediso Medical Imaging Systems today announced that it has completed the technology transfer of the new Cameleon4™ MRI spectrometer developed by RS2D (Strasbourg, France).

Following the IP transfer, the new console is seamlessly integrated into the nanoScan® cryogen-free 3T and 7T MRI product line resulting in superior imaging performance. Financial terms of the agreement were not disclosed.

For the past seven years Mediso and RS2D partnered in a technology license and commercial agreement to deliver the new line of nanoScan® 3T and 7T MRI systems all based on a patented truly cryogen-free superconducting magnet technology. In 2019 parties extended their collaboration further into a Technology Transfer deal providing access to the entire IP for Mediso.

Gergő Bagaméry, Director of Preclinical Product Development at Mediso commented: “Keeping the know-how of core imaging technologies was always essential for Mediso. This agreement strengthens MRI as a core-competence, along with PET, SPECT and CT, thus completing the entire imaging portfolio. In the past years we invested significant resources to build an MRI electronics and sequence development team and this technology allows us to bring novel, high-end MRI applications to the market.”

Rémy Schimpf, Senior VP Sales at Nanalysis and RS2D founder, commented: “We have had a fruitful relationship with Mediso over the past seven years, and we look forward to continuing to strengthen the relationship for many years to come. Through our reinforced R&D team in Strasbourg, we have introduced the fourth generation of spectrometer the Cameleon4™ that allows us to continue to expand our horizons for all NMR and MRI applications.”

Mediso has been a major player in medical imaging for 30+ years with a high profile of development, manufacturing, selling and servicing multi-modality imaging devices. Beyond the market leading nanoScan PET/CT and SPECT/CT, Mediso launched the world’s first integrated PET/MRI and SPECT/MRI systems. By adding the 3T and 7T truly cryogen-free magnets and the SiPM based PET insert to the product line, the nanoScan family has the largest install base of integrated PET/MRI systems.

Nanalysis Corp., Calgary, Canada, is an industry leader in developing and manufacturing compact NMR spectrometers for laboratory and industrial markets. Its cutting edge 60 and 100 MHz spectrometers require no liquid cryogens. Through its European subsidiary RS2D, the Company develops his own proprietary hardware and software that are being incorporated into next-gen MRI and NMR systems.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy